相关实验视频

Updated: Jan 16, 2026

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

肠道微生物群调解SGLT-2抑制剂对双相情感障碍的保护作用:一项中介门德尔随机化研究

Yunchang Yang¹, Yunqin Sun¹, Yaofeng Wang¹

¹North Henan medical university, Xinxiang,China.

Physiology & behavior

|October 5, 2025

概括

这项研究表明,SGLT-2抑制剂可能会降低双相情感障碍 (BD) 风险,可能是通过调节肠道微生物群,如Clostridium sporosphaeroides. 需要进一步的研究来验证.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
微生物学微生物学

背景情况:

双极性障碍 (BD) 影响全球约1%,涉及情绪波动和社会障碍.
病因包括遗传学,大脑结构和肠-大脑轴失调.
在BD中SGLT-2抑制剂和肠道微生物群的作用尚不清楚.

研究的目的:

调查SGLT-2抑制剂,肠道微生物群和BD风险之间的因果关系.
识别特定的肠道微生物,调解这种关系.
阐明涉及的分子通路.

主要方法:

使用两个样本的孟德尔随机化 (MR) 与欧洲GWAS数据.
采用逆变量加权回归和灵敏度分析.
进行过调解,功能丰富,基因表达和网络分析.

主要成果:

SGLT-2 抑制剂对 BD 风险产生显著的保护作用 (OR=0.104).
这种效应部分是由 *Clostridium sporosphaeroides* 丰富度介导的.
368种肠道微生物群与BD有因果关联;信号传递和神经活性联体受体通路都与此有关.

结论:

提供SGLT-2抑制剂降低BD风险的遗传证据,部分通过*Clostridium Sporosphaeroides*.
突出了在BD病变发生过程中代谢和免疫因素之间的相互作用.
建议潜在的治疗途径包括SGLT-2抑制剂和微生物群调节.

关键词:

双极性障碍是一种双极性障碍.肠-大脑轴肠-大脑轴肠道菌群是什么意思肠道菌群门德尔的随机化 SGLT-2 抑制剂的使用.

更多相关视频

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

Murine Fecal Isolation and Microbiota Transplantation

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

相关概念视频

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...